A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma

Trial Profile

A 6-month Randomized, Double-blind, Parallel-group, Multicentre, Placebo-controlled Phase II Study to Compare Anti-asthmatic Effect and Safety of Esomeprazole (Nexium) 40 mg Twice Daily or 40 mg Once Daily With Placebo in Adults With Asthma

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications Asthma; Gastro-oesophageal reflux
  • Focus Pharmacodynamics
  • Acronyms RELAX
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Jan 2010 Results published in the American Journal of Respiratory and Critical Care Medicine.
    • 30 May 2009 Results presented at Digestive Disease Week (DDW) 2009.
    • 26 Feb 2008 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top